Mavorixafor is a small molecule commercialized by Abbisko Therapeutics, with a leading Pre-Registration program in WHIM Syndrome (Warts, Hypogammaglobulinemia, Infections and Myelokathexis). According to Globaldata, it is involved in 13 clinical trials, of which 6 were completed, 3 are ongoing, 2 are planned, and 2 were terminated. GlobalData uses proprietary data and analytics to provide a complete picture of Mavorixafor’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
Smarter leaders trust GlobalData
The revenue for Mavorixafor is expected to reach an annual total of $76 mn by 2033 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Mavorixafor Overview
Mavorixafor (X4P-001) is under development for the treatment of severe congenital neutropenia, Waldenstrom’s Macroglobulinemia, WHIM syndrome, melanoma and refractory solid tumors including clear cell renal cell carcinoma (ccRCC) and triple-negative breast cancer. It is administered through oral route. The drug candidate was under development for the treatment of human immunodeficiency virus (HIV) Infections (AIDS). The drug candidate acts by targeting C-X-C receptor type 4 (CXCR4).
Abbisko Therapeutics Overview
Abbisko Therapeutics (Abbisko) is a biopharmaceutical company. It discovers and develops of novel medicines to the treatment of cancers and other diseases. Its pipeline products include ABSK011, ABSK021 among others. ABSK011 developed for the treatment of advanced HCC with hyperactivation of FGF19/FGFR4 signaling. ABSK021 is for the treatment of adult patients with TGCT, pancreatic cancer, colorectal cancer, cGvHD and ALS. It offers services such as drug discovery development and clinical trials. It owns an integrated research and development center in Shanghai Zhangjiang Hi-Tech Park to conduct immune-oncology drug development activities. Abbisko is headquartered in Shanghai, China.
The operating loss of the company was CNY492.9 million in FY2022, compared to an operating loss of CNY1,809 million in FY2021. The net loss of the company was CNY495.6 million in FY2022, compared to a net loss of CNY1,810 million in FY2021.
For a complete picture of Mavorixafor’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.
The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.
